Skip to main content

Table 2 Expected number of newly diagnosed U.S. patients by HLA-1 type and cancer entity

From: Identification and ranking of recurrent neo-epitopes in cancer

A)              
Cancer entity Study Number of patients HLA-A*01:01 (7.61%) HLA-A*02:01 (20.36%) HLA-A*03:01 (6.60%) HLA-A*11:01 (4.37%) HLA-B*07:02 (6.51%) HLA-B*08:01 (4.80%) HLA-B*15:01 (4.46%) HLA-C*04:01 (16.69%) HLA-C*06:02 (5.72%) HLA-C*07:01 (9.28%) HLA-C*07:02 (15.39%)
Bladder Urothelial Carcinoma BLCA 69300 340 638 197 152 142 112 89 223 376 596 383
Invasive Breast Carcinoma BRCA 204800 110 1090 461 199 108 375 120 482 1411 2305 1234
Cervical Squamous Cell Carcinoma CESC 14000 58 135 16 17 13 14 23 142 27 66 152
Colon Adenocarcinoma COAD 154840 861 1628 770 760 450 222 375 2961 1019 1620 1800
Esophageal Adenocarcinoma ESCA 4750 23 151 26 16 20 5 13 101 23 26 83
Glioblastoma Multiforme GBM 3204 7 17 3 7 0 0 3 8 5 3 3
Head & Neck Squamous Cell Carcinoma HNSC 58000 43 208 112 45 81 11 81 301 136 220 175
Renal Clear Cell Carcinoma KIRC 57600 13 70 23 0 0 8 0 0 10 0 26
Papilliary Renal Cell Carcinoma KIRP 8064 0 6 0 3 0 0 0 29 0 0 0
Acute Myeloid Leukemia LAML 13500 77 115 0 8 49 0 0 0 48 9 73
Hepatocellular Carcinoma LIHC 29700 12 496 131 84 69 12 7 68 69 112 174
Lung Squamous Cell Carcinoma LUSC 66000 181 642 328 168 282 13 77 593 151 172 366
Serous Ovarian Cancer OV 16800 26 24 33 10 15 2 14 39 9 14 36
Prostate Adenocarcinoma PRAD 260000 120 852 69 69 34 50 70 175 387 628 1202
Melanoma SKCM 75000 2649 7890 1817 936 861 530 203 2186 438 1000 2457
Stomach Adenocarcinoma STAD 25000 47 172 56 66 26 8 30 206 114 166 130
Thyroid Cancer THCA 46400 394 0 0 0 0 14 0 0 0 0 44
Endometrial Carcinoma UCEC 55000 942 2804 817 501 369 290 493 2222 856 1602 1779
Total   1161958 5904 16936 4858 3033 2517 1666 1598 9736 5080 8539 10116
B)              
Number of candidates in diseases    55 91 68 64 33 24 24 48 48 50 55
  1. A) Expected number of patients of a given HLA-1 type who harbor at least one potentially immunogenic neo-epitope candidate for that HLA-1 type. Both the cancer incidence and the allele frequency are estimated for the U.S. population. The probability that a patient carries at least one variant from the set of neo-epitope candidates is computed under the assumption that the occurrence of variants in a cancer patient stems from statistically independent events. B) Number of neo-epitope candidates identified in the 18 studies shown in A, which are predicted to be strong binders to the corresponding HLA-1 type